CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer

Naminatsu Takahara, Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Kei Saito, Kensaku Noguchi, Tatsunori Suzuki, Tomoka Nakamura, Tatsuya Sato, Kazunaga Ishigaki, Ryunosuke Hakuta, Tsuyoshi Takeda, Rie Uchino, Suguru Mizuno, Hirofumi Kogure, Minoru Tada, Kazuhiko Koike

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Purpose: The role of carbohydrate antigen 19-9 (CA19-9) kinetics in patients with biliary tract cancer (BTC) receiving chemotherapy remains to be elucidated. Methods: A total of 185 advanced or recurrent BTC patients receiving a first line chemotherapy between January 2006 and March 2016, were retrospectively studied. Serum CA19-9 was measured at baseline and after two cycles of chemotherapy, and patients were categorized based on CA19-9 response: CA19-9 decrease group (≥ 30% decrease), stable group (< 30% decrease and < 20% increase) and increase group (≥ 20% increase). The associations of CA19-9 response with radiological tumor response, progression-free survival (PFS) and overall survival (OS) were investigated. Results: There was a statistically significant association between CA19-9 response and radiological tumor responses (p < 0.001). The median PFS and OS were significantly different among three groups according to CA19-9 response: PFS of 8.0, 5.7 and 3.5 months in CA19-9 decrease, stable and increase groups (p < 0.001) and OS of 18.8, 16.0 and 7.5 months in CA19-9 decrease, stable and increase groups, respectively (p < 0.001). Multivariate analyses showed that CA19-9 response was prognostic both of OS and PFS in addition, to CA19-9 at baseline, and performance status. Conclusion: CA19-9 kinetics after the first two cycles of a first line chemotherapy was a prognostic factor for OS and PFS in patients with advanced and recurrent BTC.

Original languageEnglish
Pages (from-to)1105-1112
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Issue number6
Publication statusPublished - 1 Dec 2017
Externally publishedYes


  • Biliary tract cancer
  • Carbohydrate antigen 19-9
  • Chemotherapy
  • Prognostic factors
  • Retrospective study


Dive into the research topics of 'CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer'. Together they form a unique fingerprint.

Cite this